AbbVie Market Cap Analysis and Trends

AbbVie's market capitalization has been steadily increasing over the years, reaching a peak of over $200 billion in 2022. This growth can be attributed to the company's strong portfolio of pharmaceuticals.

One of the key drivers of AbbVie's market capitalization is its flagship product, Humira, which generates over $19 billion in annual sales. This makes it one of the top-selling pharmaceuticals in the world.

AbbVie's market capitalization has also been influenced by its strategic acquisitions, including the purchase of Allergan in 2020. This deal expanded AbbVie's presence in the dermatology and ophthalmology markets, further increasing its market value.

As a result, AbbVie has become one of the largest and most successful pharmaceutical companies in the world, with a market capitalization that continues to grow and evolve.

Here's an interesting read: Abbvie Ventures

AbbVie's market capitalization has shown significant growth over the years, with a yearly average increase of 15.45% from 2014 to 2025.

The market capitalization has fluctuated, with a high of $413.22 billion in October 2025 and a low of $142.60 billion in January 2020.

AbbVie's market capitalization has consistently ranked among the top 50 companies globally, with a highest rank of 23 in October 2025.

Here's a breakdown of AbbVie's market capitalization growth from 2014 to 2025:

Market Capitalization, often referred to as Market Cap, is a widely used metric to gauge a company's size. $414.49 B is the Market Capitalization of AbbVie.

Enterprise Value, on the other hand, takes into account a company's entire capital structure, including debt and equity. AbbVie's Enterprise Value is $392.93 B.

Market Cap is calculated by multiplying the current share price by the total number of shares outstanding. Enterprise Value, however, is the sum of Market Cap, Total Debt, and subtracting Cash.

Enterprise Value is a more comprehensive measure of a company's total value, making it the preferred valuation method for mergers and acquisitions.

Recommended read: Dow Jones U.s. Large-cap Growth Total Stock Market Index

AbbVie's market capitalization has seen significant growth over the years, with a yearly evolution that's worth examining.

In 2025, AbbVie's market capitalization reached $301.60 billion, marking a 5.80% year-over-year (YoY) increase from 2024.

Here's a breakdown of AbbVie's market capitalization growth:

As you can see, AbbVie's market capitalization has experienced significant fluctuations over the years, with some years seeing substantial growth and others experiencing declines.

AbbVie's market capitalization peaked at $413.22 billion in October 2025, representing a 37.48% increase from the previous year.

The company's market capitalization has also been impacted by its global ranking, with a high of 23rd place in October 2025, down from 30th place in December 2024.

Abbvie is a multinational biopharmaceutical company founded in 2013 after the separation of Abbott Laboratories into two separate companies. It's headquartered in North Chicago, Illinois.

The company's name is derived from the words "Abbott" and "Vie", which means "life" in French. This reflects the company's mission to improve people's lives through innovative medicines.

Abbvie's main focus is on developing and commercializing medicines for various diseases, including immunology, oncology, virology, and neuroscience. Its portfolio includes well-known brands like Humira, Lupron, and AndroGel.

The company's revenue for 2020 was over $48 billion, making it one of the largest biopharmaceutical companies in the world.

Consider reading: Abbott Labs Market Cap